On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Weekly Release  2006: Volume 11/ Issue 4 Article 6
Back to Table of Contents

Eurosurveillance, Volume 11, Issue 4, 26 January 2006

Citation style for this article: Aboulhab J. HBV viral load is an independent predictor of progression to hepatocellular carcinoma in chronic HBV patients. Euro Surveill. 2006;11(4):pii=2887. Available online:

HBV viral load is an independent predictor of progression to hepatocellular carcinoma in chronic HBV patients

Jamila Aboulhab (, Health Protection Agency Centre for Infections, London, United Kingdom

The risk of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) viral load, according to a Taiwanese study [1]. This association was shown to be independent of other risk factors, and to have a dose-response relationship. The study also showed that HBV DNA levels were persistently elevated in patients at highest risk of liver cancer.

HBV infection is endemic in Taiwan. It is usually acquired perinatally or in early childhood. An earlier small case-control study had found a significant association between HBV viral load and risk of liver cancer in individuals who were HBeAg negative (a marker of HBV active replication in chronic HBV infected patients). To confirm this finding, the authors conducted a long-term, follow-up, population-based, prospective study of 3653 individuals who were HBsAg seropositive (and HCV antibodies seronegative) at baseline. The study’s aim was to assess the biological gradient of HCC risk by HBV viral load at entry and the effect of persistent high HBV viral load on this risk.

The study was conducted within a community-based cancer-screening programme, between 1991 and 2004. Out of 89 293 subjects invited to participate during 1991-92, 23 820 (27%) accepted, 4155 (17%) of these were HBsAg positive, and 3653 (88%) of the HBsAg positive participants were anti-HCV negative and provided sufficient serum at baseline. All were free of HCC at baseline. Participants were aged between 30 and 65 years (67% older than 39 years). The majority were male (62%), never smoked (66%), never drank alcohol (87%), had a serum alanine aminotransferase (ALT) level of <45U/L (94%), were seronegative for HbeAg (85%) and free of cirrhosis (98%).

There were 164 incident cases of hepatocellular carcinoma and 346 deaths during follow up (mean follow up of 11.4 years and a total of 41 779 person-years). The incidence of HCC increased with baseline HBV viral load in a dose-response relationship ranging from 108 /100 000 person years for undetectable viral load (<300 copies/mL) to an incidence of 1152/100 000 person years for an HBV viral load >1 million copies/mL. The cumulative incidence rates of HCC were 1.3% and 14.9%, respectively. The biological gradient remained significant after adjusting for other risk factors (sex, age, smoking, alcohol consumption, HBeAg serology, ALT level, and liver cirrhosis at baseline). The dose-response association was strongest for participants who were HBeAg seronegative and with normal ALT and no liver cirrhosis at baseline. Participants with persistent high HBV viral load during follow-up had the highest HCC risk.

HBV antiviral treatment was not available in Taiwan until 2003. To the knowledge of the authors, this study is one of the largest and the longest prospective studies of HBV natural history to look at HCC risk in relation to HBV viral load.

HBeAg is known to be a strong predictor of progression to HCC. In this study, the strength of the association between HBV viral load at baseline and the risk of HCC remained high after adjusting for HBeAg positivity. The majority (72%) of HBeAg seronegative participants had a detectable HBV viral load.

The prominence of HBV viral load as an independent predictor of HCC risk and the demonstration of a significant and consistent biological gradient suggest the importance of both close clinical monitoring and antiviral treatment for individuals with high HBV viral load (>10 000 copies/ml ). The authors also propose that their findings of increased risk associated with persistently high HBV viral load suggest effective antivirals could be expected to lower the risk of HCC, and that lowering HBV viral load may be seen as a good surrogate marker for slower clinical progression.

HBV genotypes B and C are predominant in Taiwan, and in this study. Genotype C has been shown to be associated with higher HBV levels and a greater risk of HCC than genotype B. The impact of genotype on the risk of HCC is the subject of ongoing study by the authors.

  1. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 65-73.

back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.